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BACKGROUND AND PURPOSE
Development of combination therapies has received significant interest in recent years. Previously, a two-receptor one-transducer (2R-
1T) model was proposed to characterize drug interactions with two receptors that lead to the same phenotypic response through a
common transducer pathway. We applied, for the first time, the 2R-1T model to characterize the interaction of noradrenaline and
arginine-vasopressin on vasoconstriction and performed inter-species scaling to humans using this mechanism-based model.
EXPERIMENTAL APPROACH
Contractile data were obtained from in vitro rat small mesenteric arteries after exposure to single or combined challenges of
noradrenaline and arginine-vasopressin with or without pretreatment with the irreversible α-adrenoceptor antagonist,
phenoxybenzamine. Data were analysed using the 2R-1T model to characterize the observed exposure–response relationships
and drug–drug interaction. The model was then scaled to humans by accounting for differences in receptor density.
KEY RESULTS
With receptor affinities set to published values, the 2R-1T model satisfactorily characterized the interaction between noradrena-
line and arginine-vasopressin in rat small mesenteric arteries (relative standard error ≤20%), as well as the effect of
phenoxybenzamine. Furthermore, after scaling the model to human vascular tissue, the model also adequately predicted the
interaction between both agents on human renal arteries.
CONCLUSIONS AND IMPLICATIONS
The 2R-1T model can be of relevance to quantitatively characterize the interaction between two drugs that interact via different
receptors and a common transducer pathway. Its mechanistic properties are valuable for scaling the model across species. This
approach is therefore of significant value to rationally optimize novel combination treatments.
Abbreviations
2R-1T, two-receptor one-transducer; AIC, Akaike information criterion; AVP, arginine-vasopressin; CH, receptor density in
human vessels; CR, receptor density in rat vessels; E/[A], concentration-effect; Emax, maximum effect; FIH, first-in-human;
GOF, goodness-of-fit; IIV, inter-individual variability; K, the total transducer amount at half-maximal effect; KAVP, affinity
of AVP on V1A receptors; KHS, Krebs–Henseleit solution; KNA, affinity of noradrenaline on α1A-adrenoceptors; mAVP/K,
maximum transducer amount that AVP can produce normalized by K; mNA/K, maximum transducer amount that nor-
adrenaline can produce normalized by K; nAVP, Hill slope index of AVP transduction pathway; nH, Hill slope index of E/[A]
curve; nM, Hill slope index of the common transduction pathway; nNA, Hill slope index of noradrenaline transduction
pathway; PBZA, phenoxybenzamine effect on α1A-adrenoceptors; PBZM, phenoxybenzamine effect on the common trans-
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Introduction
The increasing availability of targeted therapeutic agents has
raised interest in rationally developing combination thera-
pies associated with improved efficacy profiles or reduction
of side effects (Fitzgerald et al., 2006; Al-Lazikani et al.,
2012). However, the identification and characterization of
optimal drug combination regimens are not straightforward.
Mathematical approaches to characterize pharmacological
interactions between drugs have shown to be of significant
relevance to address this challenge (Jonker et al., 2005;
Danhof et al., 2007; Van Hasselt and Van Der Graaf, 2015;
Gabrielsson et al., 2016; Koch et al., 2016).
The interaction of two agonists that lead to a single
phenotypic response through different receptors and a
common transduction pathway is one common type of
drug–drug interaction. For such an interaction, a theoretical
mechanism-based model was proposed three decades ago
(Leff, 1987). According to the geometry of the agonist
concentration-effect (E/[A]) curve, this two-receptor one-
transducer (2R-1T) model can account for phenomena like
threshold amplification and potentiation and predicts the
conditions under which they will occur (Christ and Jean-
Jacques, 1991; Gerthoffer, 1996). Previously, a model based
on these principles was used to describe the effect of a sin-
gle agonist acting simultaneously at two different receptors
linked to a common transduction pathway (Van der Graaf
et al., 1996). Scaramellini then extended this model to al-
low for the interacting agonists to have E/[A] curves with
different slopes (Scaramellini et al., 1997). This approach
provides a framework that can describe another mechanism
of drug–drug interaction besides other commonly used
mechanism-based methodologies that focus primarily on
the effect of two drugs acting on one receptor (Koch et al.,
2016). However, there is still a lack of research on the appli-
cation of this framework.
Experimental models for drug-induced vasoconstriction
have been extensively used to quantitatively investigate
agonist–agonist interactions (Prins et al., 1992; Cohen and
Schenck, 2000; Lemos et al., 2002; Segarra et al., 2002;
Streefkerk et al., 2003). In the present study, we focused
on the pharmacological interaction between arginine-va-
sopressin (AVP) and noradrenaline. Noradrenaline
and AVP are two endogenous molecules involved in cardio-
vascular regulation as well as being used as clinical thera-
peutic agents to constrict blood vessels. Noradrenaline is a
typical treatment for septic shock where AVP can be added
with the intent of raising blood pressure or decreasing nor-
adrenaline dosage (Dellinger et al., 2013). We assessed if the
previously described theoretical 2R-1T framework can be
used to characterize the interaction between noradrenaline
and AVP on blood vessel contraction. Rat small mesenteric
artery (SMA) was chosen as the model system, for which it
is known that vasoconstriction induced by AVP and nor-
adrenaline is associated with the V1A vasopressin recep-
tor (Stam et al., 1998) and the α1A-adrenoceptor (Stam
et al., 1999; Pérez-Rivera et al., 2007), respectively,
involving a common transduction pathway (Mauger et al.,
1984). Furthermore, we also investigated if the
mechanism-based basis of the 2R-1T model can be utilized
to allow for translational inter-species scaling to humans.
As far as we know, the present paper is the first account




All animal care and experimental protocolswere approved by the
localAnimal Experiments Committee, under theDutchNational
Experiments on Animals Act. Animal studies are reported in
compliance with the ARRIVE guidelines (Kilkenny et al., 2010;
McGrath and Lilley, 2015), and United States NIH guidelines.
MaleWistar rats, a commonly used rat strain in pharmacological
studies, were obtained from Harlan, Zeist, The Netherlands.
Rat small mesenteric artery (SMA) preparation. Male Wistar
rats (250–350 g, 6–12 weeks) were anaesthetized (sodium
pentobarbitone, 60 mg·kg1, i.p.) and killed by cervical
dislocation. The mesentery was removed and placed in ice-
cold modified Krebs–Henseleit solution (KHS) of the
following composition (mM): NaCl 119.0, NaHCO3 25.0,
KCI 4.7, KH2PO4 1.2, MgSO4 1.2, glucose 5.5, CaCl2 2.5, and
EDTA 0.026. Arterial trees were dissected and cleared from
surrounding adipose tissue. From each arterial tree, a ring
segment (~2 mm in length) was mounted in a myograph (J.
P. Trading, Aarhus, Denmark) with separated 6 mL organ
baths containing modified KHS at 37°C. The KHS was
continuously gassed with 95% O2 and 5% CO2, as described
previously (Mulvany et al., 1977). Tissue responses were
measured continuously as changes in isometric force.
Following a 30 min stabilization period, the internal di-
ameter of each vessel was set to a tension equivalent to 0.9
times the estimated diameter at 100 mmHg effective
transmural pressure (I100 = 200–300 μm) according to the
standard procedure of Mulvany & Halpern (Mulvany et al.,
1977). After a further 30 min stabilization period, the prepa-
rations were challenged five times with noradrenaline
(10 μM) with washouts after each challenge. The presence of
the endothelium was confirmed by adding with 10 μM of
methacholine after the first challenge and tissues which
responded with less than 60% relaxation were rejected. The
contraction induced by the fifth noradrenaline challenge
was regarded as a calibration contraction in the experiment,
relative to which all subsequent responses were expressed.
This normalization eliminated absolute contractile power
differences between vessel segments that result from for ex-
ample smooth muscle content of the segments.
In all experiments, 60 min prior to construction of each
agonist E/[A] curve, a mixture of cocaine (30 μM), timolol
(6 μM) and SCH-23390 (R(+)-7-chloro-8-hydroxy-3-methyl-
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochlo-
ride; 10 nM) were added to the KHS to block neuronal uptake,
β1/β2-adrenoceptors and dopamine D1 receptors respectively
(Stam et al., 1999).
Experimental design. In general, SMAs were exposed in vitro
to single or combined challenges of noradrenaline and
AVP in varying concentrations, with or without
pretreatment with phenoxybenzamine, a non-selective
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irreversible α-adrenoceptor blocker which also has a
possible effect on calcium channels (Gengo et al., 1984;
McPherson et al., 1985).
Interaction experiments without receptor inactivation.
Concentration dependent contraction of rat SMA induced by
noradrenaline or AVP in the absence or presence of the other
drug was investigated according to the paired and single E/[A]
curve protocols developed previously for noradrenaline (Stam
et al., 1999) and AVP (Stam et al., 1998) respectively. Initial
noradrenaline E/[A] curves were first obtained (n = 19) and
were followed by 30 min washing and further equilibration for
another 45 min. Subsequently, threshold contractions that
amounted about 5, 10 or 25% of the maximum of the initial
E/[A] curves were induced by AVP through increasing drug
concentrations in small steps until desired contraction level
was reached. After stabilization of the threshold contraction,
second noradrenaline E/[A] curves were obtained. AVP E/[A]
curves with no threshold contraction or with threshold
contractions induced by noradrenaline that amounted about
5, 10 or 25% of the calibration contraction were obtained as
described above but from separate vessel segments (n = 18).
Interaction experiments with prior receptor
inactivation. In another set of experiments, the
interaction between noradrenaline and AVP on the
contraction of rat SMA was also assessed after pretreating
the vessel segments with phenoxybenzamine. Prior to the
interaction experiments, the vessel segments (n = 8) were
pretreated with phenoxybenzamine (3 nM) for 5 min and
were then washed eight times during a 30 min period and
equilibrated for 45 min. Subsequently, the E/[A] curves of
noradrenaline with or without a threshold contraction
induced by AVP that amounted about 10% of the
calibration contraction were produced as described earlier.
Randomization and blinding were not applicable as this is
not an intervention study.
Data analysis
Model development. Scaramellini and co-workers presented a
theoretical 2R-1T model which provides a quantitative
framework to interpret the interaction between two
agonists, A1 and A2, which bind to two different receptors,
R1 and R2, respectively, and produce a common intracellular
mediator M leading to a pharmacological effect E (Figure 1)
(Scaramellini et al., 1997). For the current research, we
analysed the experimental data of noradrenaline and AVP
with the 2R-1T model. The estimation of model parameters
and associated uncertainty/confidence intervals was based
on simultaneous fitting of all individual data. The data and
statistical analysis comply with the recommendations on
experimental design and analysis in pharmacology (Curtis
et al., 2018).
The 2R-1T model assumes that the intracellular mediators
[M]NA and [M]AVP amount depend on drug concentrations
and have the algebraic form of a Hill equation (Equations 1
and 2). The pharmacological effect E is derived by [M]Tot, the
summation of mediator concentrations (Equation 3), also
according to the Hill equation (Equation 4). Our
experiments also included the addition of a third drug,
phenoxybenzamine. To account for this inhibitor, two addi-
tional terms PBZA and PBZM were included (Equations 1 and
3), representing the irreversible blockade effect on








KAVPnAVP þ AVP½ nAVP
(2)
M½ Tot ¼ M½ NA þ M½ AVP
 PBZM (3)
Here, mNA and mAVP represent the maximum transducer
amount that noradrenaline and AVP can produce, respec-
tively and can be considered to represent receptor density,
[NA] and [AVP] represent the concentrations of these two
drugs, nNA and nAVP represent the Hill slope index of the two
separated transduction pathways, KNA and KAVP represent
the noradrenaline and AVP concentrations that produce
half-maximal amount of [M]NA and [M]AVP, which can be con-
sidered as the affinities of noradrenaline and AVP on α1A-
adrenoceptors and V1A receptors respectively. We considered
both estimating KNA and KAVP, and fixing these parameters to
the published values, identified as 4.27 μM (Nyborg and
Bevan, 1988) and 0.24 nM (Bockman et al., 1992) respec-
tively. PBZA and PBZM were both constrained to values be-
tween 0 and 1. In the absence of phenoxybenzamine, PBZA
and PBZM were both set to be 1 as the receptor or transducer
Figure 1
2R-1T model structure (Scaramellini et al., 1997).
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is intact. Finally, the E/[A] relationship for noradrenaline and
AVP was characterized with Equation 4:
E ¼ Emax M½ tot
nM
KnM þ M½ tot nM
(4)
Here, Emax represents the maximum possible system ef-
fect, K represents the amount of [M]tot at half-maximal value
of E, and nM represents the Hill slope index of the common
transduction pathway. The absolute value of K is unidentifi-
able, and was therefore fixed to 1, which means both numer-
ator and denominator of Equation 4 were divided by K. Thus,
the estimates of mNA and mAVP could be expressed as mNA/K
and mAVP/K.
A mixed-effect modelling approach was applied to ac-
count for inter-individual variability (IIV). Parameter esti-
mate was performed through the first order conditional
estimation method with interaction (FOCEI), implemented
in nonlinearmixed-effect modelling software NONMEM, ver-
sion 7.3.0 (ICON Development Solutions) (Keizer et al.,
2013). IIV was estimated for mNA/K, mAVP/K and Emax with
Equation 5, where Pi represents the parameter of each exper-
iment, Ptp represents typical value of the parameter, and η rep-
resents the IIV which was assumed to be log-normally
distributed with mean of 0 and variance of ω2. IIV of KNA
and KAVP were also estimated while fixing the corresponding
typical values as literature values. Residual error was charac-
terized with additive error model with Equation 6, where
Yobs_i represents observations, Ypred_i represents predictions,
and ε represents the residual error which was also assumed
to log-normally distributed withmean of 0 and variance of σ2.
Pi ¼ Ptpeηi (5)
Yobs i ¼ Ypred i þ εi (6)
Precision of parameter estimates, which was reflected by
relative standard error (RSE) of parameters, and the Akaike in-
formation criterion (AIC) were regarded as the criteria to as-
sess the goodness-of-fit (GOF) of model. Standard GOF plots
and a visual predictive check (VPC) were also used to assess
the model performance (Nguyen et al., 2017).
Translation to human contractile data. We investigated the
extrapolation of the model to human data by adjusting
parameters mNA/K and mAVP/K according to the difference in
receptor density of α1A-adrenoceptors and V1A receptors
between rat and human vessels (Eq. 7), while KNA and KAVP
were kept unchanged:
PH ¼ PRCHCR (7)
Here, PH and PR represent parametermNA/K and mAVP/K for
human and rat respectively, and CH and CR respectively repre-
sent the receptor density in human and rat vessels. CH and CR
were reported respectively as 61.6 fmol·mg1 of protein
(Yamada et al., 1994) and 101 fmol·mg1 of protein (Faber
et al., 2001) for α1A-adrenoceptors and 36 fmol·mg
1 of pro-
tein (Serradeil-Le Gal et al., 1995) and 52 fmol·mg1 of pro-
tein (Vågnes et al., 2004) for V1A receptors, making the ratio
CH/CR 0.61 and 0.69 for α1A-adrenoceptors and V1A receptors
respectively.
Drug induced E/[A] curves in human were derived from
published data where human renal arterial rings were
challenged ex vivo with noradrenaline with or without small
concentrations of AVP (0.1 and 0.03 nM) (Segarra et al.,
2002). The data points were digitized by WebPlotDigitizer,
version 3.11 (http://arohatgi.info/WebPlotDigitizer/app/).
The scaled model performance was assessed by comparing
the result of 500 simulations with observed human data.
The predictive performance of the model without any scaling
for receptor density was also assessed as a comparison.
Contractile responses in the human study were expressed
relative to a response to 100 mM KCl, the relative level of
which differs from that of the calibration contraction (i.e.
the response to 10 μM noradrenaline) used in our rat experi-
ment. Therefore, to make the scaled model predictions be
comparable with the human data, the simulation results were
adjusted through beingmultiplied by the human contraction
response induced by 10 μM noradrenaline, which was 150%
of the response to 100 mM KCl.
Sensitivity analysis was performed to evaluate the effects
of receptor density ratios and drug affinity values on the
scaled model predictions respectively. The CH/CR ratio of
α1A-adrenoceptors and V1A receptors as well as KNA and KAVP
were set as 0.5-fold, onefold and twofold of the original
values, respectively, and the prediction results were assessed
by plotting population prediction results together with the
human experimental data where human vessels were chal-
lenged with noradrenaline and 0.1 nM of AVP.
Materials
[Arg8] vasopressin, cocaine hydrochloride, methacholine bro-
mide, l-noradrenaline hydrochloride, phenoxybenzamine hy-
drochloride and timolol maleate were purchased from Sigma,
Zwijndrecht, the Netherlands. SCH 23390 were purchased from
Research Biochemicals Incorporated, Natick, USA. Noradrena-
line was dissolved in stoichiometric ascorbic acid solution.
Methacholine and phenoxybenzamine were dissolved in etha-
nol, and the final amount of ethanol in organ bath was <1‰
which causes no extra relaxation on the vessel segments (Ru
et al., 2008). All other drugs were dissolved in distilled water.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander et al., 2017).
Results
Effects of noradrenaline, AVP and
phenoxybenzamine on contraction
Noradrenaline caused concentration-dependent contrac-
tions of SMAs (Figure 2A). Individual E/[A] curves were fitted
to the Hill equation as described in Stam et al. (1998, 1999) to
obtain estimates of midpoint location (pEC50 = log (EC50)
Quantitative analysis of noradrenaline and AVP interaction
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and Hill slope (nH). Threshold contractions that amounted to
5.5 ± 0.6% (mean ± SD, n = 4), 12.4 ± 2.3% (n = 8) and
28.4 ± 4.2% (n = 7) of the calibration contraction were induced
by 0.13 ± 0.1, 0.08 ± 0.03 and 0.09 ± 0.08 nM AVP respectively.
The three threshold contractions to AVP caused a >twofold
flattening of the control noradrenaline E/[A] curves [nH
changed from 2.67 ± 0.67 (n = 19) to 1.04 ± 0.17, 0.81 ± 0.10
and 0.75 ± 0.06, respectively], and a leftward shift of up to
~fourfold (pEC50 changed from 6.57 ± 0.23 to 6.89 ± 0.29,
7.16 ± 0.32 and 7.15 ± 0.38, respectively), without changing
the maximum response (Figure 2A).
AVP also caused concentration-dependent contractions
of SMAs (Figure 2B). Pre-incubating with 0.07 ± 0.05 (n = 4),
0.08 ± 0.03 (n = 5) and 0.21 ± 0.08 (n = 5) μM noradrenaline
produced threshold contractions that amounted to
6.0 ± 2.2, 11.2 ± 1.6 and 24.0 ± 3.2% of the calibration con-
traction respectively. The three threshold contractions to nor-
adrenaline also caused a >twofold flattening of the AVP E/[A]
curves compared to control [nH changed from 2.31 ± 1.4
(n = 4) to 1.08 ± 0.17, 0.85 ± 0.17 and 0.83 ± 0.08, respec-
tively], and a leftward shift of up to ~3.5-fold (pEC50 changed
from 9.71 ± 0.32 to 9.96 ± 0.18, 10.22 ± 0.26 and 9.87 ± 0.28,
respectively), without changing the maximum response
(Figure 2B). The reported n numbers were used only for data
display and calculation of SD and not for any statistical
comparison.
Pretreating with phenoxybenzamine reduced the maxi-
mum noradrenaline-induced contraction from 111 ± 4.8 to
10 ± 10.3% (n = 8) and caused a rightward shift of the nor-
adrenaline E [A] curves (Figure 2C). When AVP was added,
the noradrenaline E/[A] curves were potentiated and flat-
tened with maximum contraction increased to 49 ± 15.1%
(n = 8) (Figure 2C).
In addition to the well-established inhibitory effect of
phenoxybenzamine on noradrenaline (Van der Graaf and
Stam, 1999), when plotting AVP-induced E/[A] curves to-
gether with AVP-induced threshold contractions with or
without presence of phenoxybenzamine, the combination
of AVP with phenoxybenzamine also appeared to be associ-
ated with an inhibitory effect (Figure 2D).
Model development and evaluation
In their theoretical paper, Scaramellini et al. (1997) demon-
strate that the 2R-1T model predicts a variety of patterns of
Figure 2
Concentration dependent contraction curves induced by (A) noradrenaline (NA) in the absence of AVP (n = 19) and presence of AVP (n = 19, con-
centration range from 0.025 to 0.275 nM); (B) AVP with absence of noradrenaline (n = 4) and presence of noradrenaline (n = 14, concentration
range from 30 to 280 nM); and (C) noradrenaline with absence of AVP (n = 8) and presence of AVP (n = 8, concentration range from 0.08 to
0.8 nM) while 3 nM phenoxybenzamine (PBZ) was present. (D) E/[A] curves induced by AVP without thresholds (n = 4) and the threshold contrac-
tions induced by AVP without (n = 14) or with (n = 8) pretreatment with 3 nM phenoxybenzamine. When phenoxybenzamine was present, higher
AVP concentration was needed to reach the same contraction level as when phenoxybenzamine was absent. Responses were expressed as per-
centages of the contraction induced by the fifth previous noradrenaline (10 μM) challenge.
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agonist E/[A]-curve location and slope changes induced by
the presence of another agonist. Our data (leftward shift,
flattening and no change in maximum response) are entirely
consistent with the scenario for two full agonists which share
a common transduction pathway with a steep slope. We
therefore developed our further analysis of the data on the
basis of this 2R-1T model framework.
The parameter estimates obtained after fitting the exper-
imental data to the 2R-1T model are shown in Table 1. Two
models were considered. In Model 1, all parameters were es-
timated but the RSEs of mAVP/K and KAVP were >100%, indi-
cating that the information our experimental data provided
could not support precise estimation of these parameters.
Nonetheless, KNA could be estimated with better precision
(RSE = 26%) and was close to the previously reported values
(Nyborg and Bevan, 1988). Other parameters were esti-
mated with acceptable precision (RSE < 25%). After fixing
the typical value of KNA and KAVP to published values while
estimating corresponding IIV (Model 2), all model parame-
ters could be estimated with greater precision (RSE ≤ 20%).
The AIC of Model 2 was 3777 and was 22 lower than that
of Model 1, which was 3799, indicating that Model 2 had
better GOF than Model 1. Therefore, the model with fixed
KNA and KAVP was selected to characterize our experimental
dataset. Model evaluation results of Model 2 are shown in
Figures 3 and 4. Both population predictions and individual
predictions were comparable to the observations (Figure 3A,
B), and no trends were observed in the conditional
weighted residuals (Figure 3C). The VPC plots (Figure 4),
where model simulations were plotted together with ob-
served data points for different dose regimens, showed that
most observations could be adequately covered within the
97.5th and 2.5th percentiles of model simulations, and
the 50th percentiles of observations could mostly fit within
the 95% confidence intervals of the 50th percentiles of
simulations, although wider simulation confidence inter-
vals were shown in Figure 4C, E, F due to the fewer curves
involved in the corresponding scenarios. Using the devel-
oped model, the interactions between noradrenaline and
AVP concentrations on contraction can be visualized using
a response surface plot (Figure 5).
The extent of phenoxybenzamine inhibitory effects were
also estimated in the model. It was identified that the
addition of 3 nM phenoxybenzamine reduced the
noradrenaline-induced contractions by 92.6% and reduced
AVP-induced contractions by 44.3%.
Prediction of the contractile response of human
vessels
According to the simulation results, the model derived from
rat experimental data could not successfully capture experi-
mental data for human renal arteries assuming a 1–1 cross-
species translation with identical parameters (Figure 6A, B).
However, after adjusting mNA/K and mAVP/K by accounting
for the differences in receptor density between species, hu-
man data were shown to be adequately described by the
model (Figure 6C, D).
The results of sensitivity analysis showed that compared
with changing drug affinity values, a change in receptor den-
sity ratio appeared to have a greater overall effect on 2R-1T
model scaling results. Half reduction or a twofold increase
of original α1A-adrenoceptor CH/CR ratio, as well as a twofold
increase of original V1A receptor CH/CR ratio resulted in appar-
ently inferior prediction of human data (Figure 7), while half
reduction of original V1A receptor CH/CR ratio only slightly
changed the accuracy of predictions. In contrast, halving
original KNA or KAVP values resulted in less accurate predic-
tions, while doubling original KNA or KAVP values affected
the scaling results less (Figure 8).
Table 1
Parameter estimates of the model where KNA and KAVP were not fixed (Model 1) and where KNA and KAVP were fixed (Model 2)
Model 1 Model 2
Estimates RSE% IIV (CV%) Estimates RSE% IIV (CV%)
Parameter
mNA/K () 8.35 13.2 34.8 7.56 8.3 25.5
nNA () 0.658 4.7 – 0.665 3.8 –
mAVP/K () 8.59 189.8 44.3 1.75 6.9 27.0
nAVP () 0.495 14.5 – 0.690 7.1 –
KNA (10
6 M) 5.65 26.4 – 4.27 FIX – 51.6
KAVP (10
9 M) 18.1 478.5 – 0.24 FIX – 91.2
Emax (%) 105 2.0 9.0 108 1.4 8.0
nM () 3.77 5.4 – 3.75 5.3 –
PBZA 0.120 24.1 – 0.132 20.4 –
PBZM 0.585 14.9 – 0.557 11.6 –
Residual errors
ADD (SD, %) 4.66 – – 4.53 – –
ADD, additive error; CV, coefficient of variation; IIV, inter-individual variability.
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Discussion
The previously proposed 2R-1T model provides an attractive
quantitative framework to characterize drug–drug interac-
tions in a mechanism-based fashion. Unlike other commonly
used mechanism-based modelling methodologies (Koch
et al., 2016), the 2R-1Tmodel allows the description of the in-
teraction between two agonists acting on different receptors.
Meanwhile, in comparison with fully mechanistic ordinary
differential equation models that concern complex receptor
bindings and underlying signalling pathways (Bianconi
et al., 2012), the 2R-1T model is simpler to be implemented
as less prior knowledge is required. In this study, we have
shown that this model can indeed be used to successfully de-
scribe the interaction between two agonists of interest that
share a common transduction pathway and scale to human,
Figure 3
GOF plots for the final model, including observations versus population predictions (A), observations versus individual predictions (B), and con-
ditional weighted residual errors (CWRES) versus population predictions (C). Locally weighted scatterplot smoothing (LOWESS) regression lines
were also plotted.
Figure 4
Visual predictive check of the final model stratified on different dose regimens: (A) noradrenaline (NA) only; (B) noradrenaline with fixed concentrations
of AVP; (C) AVP only; (D) AVP with fixed concentrations of noradrenaline; (E) noradrenaline only when phenoxybenzamine (PBZ) was added; (F)
noradrenaline with fixed concentrations of AVP when phenoxybenzamine was added. Light grey hatching represents 95% confidence interval of the
2.5th and 97.5th percentile of simulations, and dark grey hatching represents 95% confidence interval of the 50th percentile of simulations.
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using a case example for contractile responses induced by
noradrenaline and AVP.
The 2R-1T model structure assumes the combination ef-
fect was derived by the summation of mediator concentra-
tions, which matches the pharmacological mechanisms of
noradrenaline and AVP-induced vasoconstriction. The esti-
mates ofmNA/K andmAVP/K were much larger than 1, indicat-
ing that the concentrations of transducer ([M]NA and [M]AVP)
produced by noradrenaline or AVP are able to reach satura-
tion of the E/[A] curves. This is consistent with the fact that
although the contractions of rat SMA induced by noradrena-
line and AVP were mutually potentiated, the maximum ef-
fects (Emax) induced by either drug alone or in combination
were similar (Figure 2). Estimates of nNA and nAVP indicated
that the slope of transducer production for noradrenaline
and AVP was similar. The slope change of noradrenaline or
AVP E/[A] curves that occurred when the other drug produced
a certain level of threshold could be captured by the estimate
of nM, as was shown in the simulation results of the initial
theoretical model (Scaramellini et al., 1997).
As there is no irreversible antagonist available for V1A re-
ceptors (Lolait et al., 2018), the E/[A] curves required to esti-
mate KAVP and mAVP/K were not obtained, which was
Figure 5
Response surface plot for the predicted contraction of different com-
binations of noradrenaline (NA) and AVP as predicted by the devel-
oped 2R-1T model.
Figure 6
Prediction of human vasoconstriction data under challenging with noradrenaline (NA) only (A and C) and noradrenaline with two different con-
centrations of AVP (0.1 and 0.03 nM) (B and D), based on the model without extrapolation (A and B) and with scaled receptor capacities, where
the scaling term on mNA/K and mAVP/K were 0.61 and 0.69 respectively (C and D). Grey hatching represents 95% confidence interval of the 50th
percentile of simulations.
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considered to be the main reason why KAVP (RSE = 478.5%)
and mAVP/K (RSE = 189.8%) could not be estimated with ac-
ceptable accuracy (Table 1, Model 1). Therefore, the value of
KNA and KAVP was ultimately fixed according to published
values. The reported value of KNA in rat SMA was identified
as 0.66–4.27 μM (Nyborg and Bevan, 1988; Oriowo et al.,
1989; Van der Graaf and Stam, 1999) and that of KAVP was
identified as 0.16–1.25 nM (Lariviere et al., 1989, 1988;
Gopalakrishnan et al., 1991; Bockman et al., 1992). Besides
the values we applied, using other identified values to fit
the data showed to have inferior GOF results (AIC increased
by 1 to 114). Therefore, the values of KNA and KAVP were
finally set as 4.27 μM (Nyborg and Bevan, 1988) and
0.24 nM (Bockman et al., 1992), respectively, to fit our
experimental data.
The use of a mixed-effect model was of particular rele-
vance to account for the IIV of the data as it may lead to bias
in parameter estimates if the variance between individual
vessel segments were not considered appropriately. The IIV
of the maximum effect was small, while for mNA/K, mAVP/K,
KNA and KAVP it was more pronounced, which was considered
to primarily account for the variability among observations.
The IIV of PBZA and PBZM was too small to be identified, thus
they were not included in our model. This population analy-
sis approach also allowed us to analyse all individual data si-
multaneously which dealt with the unequal number of
E/[A] curves for noradrenaline and AVP result from the paired
and single curve protocols effectively.
The effect of phenoxybenzamine was characterized by
two independent terms, which respectively refers to (i) the
inactivation effect on α1A-adrenoceptors and (ii) the inhibi-
tion effect on the common signal transducer for both nor-
adrenaline and AVP stimulus to account for
phenoxybenzamine caused contraction decrease for both
noradrenaline and AVP. This is in accordance with the
underlying mechanism that phenoxybenzamine as a non-
selective irreversible α-adrenoceptor blocker has
well-established inhibitory effect on noradrenaline through
α1A-adrenoceptors (Van der Graaf and Stam, 1999), and
phenoxybenzamine was also reported previously to have
an inhibition effect on calcium channels (Gengo et al.,
1984; McPherson et al., 1985) and calmodulin (Conant
et al., 2003). These latter mechanisms were considered to
contribute to phenoxybenzamine inhibition of AVP-induced
contraction shown in Figure 2D as well as on noradrenaline,
as calcium is a common signal transducer of noradrenaline
and AVP (Mauger et al., 1984). This current approach re-
sulted in a significantly better fit of the overall data (AIC de-
creased 8.7) comparing with only using one term to describe
the effect of phenoxybenzamine. The results shown in GOF
and VPC plots confirmed the satisfactory fit and predictive
performance of our model.
Figure 7
Sensitivity analysis for evaluating the effects of receptor density ratios (CH/ CR) on the scaled model predictions. The CH/CR ratio of
α1A-adrenoceptors and V1A receptors were set as 0.5-fold, onefold and twofold of the original using values. Population predictions were plotted
together with the human experimental data where human vessels were challenged with noradrenaline (NA) and 0.1 nM of AVP.
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The main limitation of our study is inherent to the
in vitro assay system used and the fact that measurements
were only obtained at (pseudo) steady-state conditions,
which does not take into account the role of time-
dependent changes in pharmacokinetics and pharmacody-
namics and feedback mechanisms present in intact in vivo
models. In addition, receptor binding kinetics (de Witte
et al., 2016) and receptor turnover (Dua et al., 2015) were
not considered in the current 2R-1T model, because no ev-
idence was observed for slow-onset or (de)sensitization of
the effect (Van der Graaf et al., 1996; Stam et al., 1999,
1998; Van der Graaf and Stam, 1999). Also, we did not ex-
plore the effect of repeated dosing in the current study. Of
course, such mechanistic elements could be added when
new data emerges that underpin the development of more
advanced versions of the 2R-1T model.
We further demonstrated that the 2R-1T model allows
inter-species extrapolation from rat to humans, indicating
that our approach can be applied in translational research.
The initial significant discrepancy between observed hu-
man data and the corresponding predictions from the
model without scaling, which assumed identical parame-
ters for rat and human, suggested an important pharmaco-
logical difference between species. Relative differences in
receptor density of blood vessels and drug affinities were
considered to be the most likely causes of this difference.
The reported range of noradrenaline and AVP affinity for
α1A-adrenoceptors and V1A receptors were from
0.40–1.58 μM (Perez et al., 2018) and 0.50–3.16 nM (Lolait
et al., 2018) respectively in humans and from 0.66–4.27 μM
and 0.16–1.25 nM respectively in rats. As the ranges of af-
finity values for human and rats overlap, KNA and KAVP
were kept unchanged during scaling. Receptor density
values, which were demonstrated to have greater influence
on the inter-species scaling of 2R-1T model from sensitivity
analysis, were derived from previous reports where the
studies were mostly performed on aortic tissue, which was
the closest related tissue where we could identify density
data. An additional suitable receptor density value for V1A
receptors was also identified as 325 fmol·mg1 of protein
for five 8-week-old rats and 45 fmol·mg1 of protein for
four 12-week-old rats (Lariviere et al., 1989), the mean of
which is 201 fmol·mg1 of protein. When applying this
mean value, the model scaling results did not change dra-
matically, as shown by the sensitivity analysis that the re-
duction of the V1A receptor CH/CR ratio did not greatly
affect the accuracy of scaling model predictions. On the ba-
sis of our current finding, the potential clinical value of
this model structure on scaling from adults to paediatrics
based on age-dependent expression of α1A-adrenoceptors
Figure 8
Sensitivity analysis for evaluating the effects of drug affinity values on the scaled model predictions. The KNA and KAVP were set as 0.5-fold, onefold
and twofold of the original using values. Population predictions were plotted together with the human experimental data where human vessels
were challenged with noradrenaline (NA) and 0.1 nM of AVP.
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and V1A receptors could be further investigated. The appli-
cability of such a system–pharmacology approach to
explaining differences between hERG-mediated QTC pro-
longation in adults and neonates on the basis of model-
predicted differences in target expression levels, which
were consistent with experimentally derived mRNA levels
in patients (Moric-Janiszewska et al., 2011), has been re-
cently demonstrated (Gotta et al., 2016).
In conclusion, we have shown, for the first time, that the
2R-1T model can be applied to characterize the interaction
between two clinically relevant agonists acting at different re-
ceptors but producing effects through a converging transduc-
tion pathway. Our data (leftward shift, flattening and no
change in maximum response) are entirely consistent with
the theoretical predictions made by Scaramellini et al.
(1997) for two full agonists which share a common transduc-
tion pathway with a steep slope. As pointed out by these au-
thors, their 2R-1T model may not be universally applicable
and is undoubtedly an oversimplification of receptor trans-
duction pathways, but our first experimental validation pro-
vided support for its validity. We therefore propose that this
simple quantitative systems pharmacology model structure
provides a translational framework to mechanistically inter-
pret and predict drug–drug interactions and is of significant
value to rationally optimize novel combination treatments.
We believe this is fully in line with the new 2017 European
Medicines Agency guideline on nonclinical and clinical as-
pects of first-in-human (FIH) and early clinical trials, which
puts more emphasis on the better use of preclinical data to
guide rational dose selection of FIH studies (Ponzano et al.,
2018; Van der Graaf and Benson, 2018).
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